Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IGHV3-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV3-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV3-20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV2-70 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV2-70 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV2-70 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV3-13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV3-13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV3-13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV2-70D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV2-70D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV2-70D sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV3-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV3-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV3-11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV2-5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV2-5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV2-5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV1-69-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV1-69-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV1-69-2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV1-69D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV1-69D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV1-69D sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV2-26 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV2-26 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV2-26 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV1-69 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV1-69 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV1-69 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV1-8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV1-8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV1-8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV1-46 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV1-46 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV1-46 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →